Amit Munshi
Chairman at ZURA BIO LIMITED
Net worth: 3 M $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Kimberly Ann Davis | F | 56 | 16 years | |
Hans Schambye | M | 59 | 13 years | |
Christopher Cabell | M | 54 | 7 years | |
Robert Lisicki | M | 57 | 5 years | |
Teofilo Raad | M | 54 |
Pulmatrix Operating Co., Inc.
Pulmatrix Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Pulmatrix Operating Co., Inc. develops pharmaceutical products for respiratory infectious diseases. Its iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer in 2003 and is headquartered in Lexington, MA. | 7 years |
Jayson Dallas | M | 56 | 7 years | |
Steven Schoch | M | 64 | 13 years | |
Mark Iwicki | M | 57 |
Pulmatrix Operating Co., Inc.
Pulmatrix Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Pulmatrix Operating Co., Inc. develops pharmaceutical products for respiratory infectious diseases. Its iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer in 2003 and is headquartered in Lexington, MA. | 7 years |
Jennifer Jarrett | F | 53 | 7 years | |
Richard Batycky | M | 56 |
Pulmatrix Operating Co., Inc.
Pulmatrix Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Pulmatrix Operating Co., Inc. develops pharmaceutical products for respiratory infectious diseases. Its iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer in 2003 and is headquartered in Lexington, MA. | 17 years |
Matthew Sherman | M | 68 |
Pulmatrix Operating Co., Inc.
Pulmatrix Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Pulmatrix Operating Co., Inc. develops pharmaceutical products for respiratory infectious diseases. Its iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer in 2003 and is headquartered in Lexington, MA. | 5 years |
Brian Goodman | M | - |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market.
Orna Therapeutics, Inc.
Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | 3 years |
Someit Sidhu | M | 34 | 2 years | |
Carl Goldfischer | M | 65 | 4 years | |
Sandeep Kulkarni | M | 43 | 2 years | |
Parvinder Thiara | M | 39 | 1 years | |
Michael Wyand | M | 68 |
Onebiopharma, Inc.
Onebiopharma, Inc. Medical/Nursing ServicesHealth Services Onebiopharma, Inc. provides health care services. The company is headquartered in Boston, MA. | - |
Garrett Winslow | M | 45 | 3 years | |
Arnout Ploos van Amstel | M | 58 | 1 years | |
Laurie Stelzer | F | 56 |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | 3 years |
Henry Danahay | M | - |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | 9 years |
Martin Gosling | M | - |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | 10 years |
Steven Marc Solomon | M | 54 | 3 years | |
Peter Finan | M | 57 |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | - |
Robert Eckert | M | 69 | 21 years | |
David Reese | M | 61 | 19 years | |
Todd Bazemore | M | 53 | 4 years | |
Ansbert Gadicke | M | 66 |
Orna Therapeutics, Inc.
Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | - |
Matthew Busch | M | 50 | 20 years | |
Biren Amin | M | 51 | 2 years | |
Chau Khuong | M | 48 | 6 years | |
Morana Jovan-Embiricos | M | 57 |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market.
Orna Therapeutics, Inc.
Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | - |
David Shapiro | M | 69 | 4 years | |
Thomas Barnes | M | - |
Orna Therapeutics, Inc.
Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | - |
John W. Ford | M | - |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | 8 years |
Daniel Anderson | M | - |
Orna Therapeutics, Inc.
Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | - |
Søren Møller | M | 56 | 4 years | |
Anne Prener | M | 66 | 3 years | |
Neil Graham | M | 65 | 1 years | |
Michael Howell | M | 47 | 2 years | |
Dave Brady | M | - | - | |
Harjit Singh | M | - | - | |
Lamine Mbow | M | - | 3 years | |
Gary Whale | M | 50 | 1 years | |
Marlyn Mathew | F | - | - | |
Jonathan Freve | M | 46 | 4 years | |
Theresa Lowry | F | 50 | - | |
Francesco Marincola | M | - |
Orna Therapeutics, Inc.
Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | - |
Gert-Jan Mulder | M | - |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | - |
Mike Zahigian | M | - | 23 years | |
David Morris | M | - |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | - |
Alexander Mayweg | M | 49 |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | - |
Sakae Asanuma | M | 57 |
Orna Therapeutics, Inc.
Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | - |
Anders Pedersen | M | 64 | 4 years | |
Derek Miller | M | - | 21 years | |
Thomas Ebeling | M | 65 |
Orna Therapeutics, Inc.
Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | 2 years |
Ciaran Lawlor | M | - |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | 3 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Keith Leonard | M | 62 | 24 years | |
Preston Klassen | M | 55 | 12 years | |
Robert Clarke | M | 56 | 15 years | |
Scott Rocklage | M | 69 | 3 years | |
Garry Neil | M | 70 | 5 years | |
John Smither | M | 71 | 15 years | |
Tina Nova | M | 70 | 18 years | |
William Duke | M | 51 | 4 years | |
David W. Beier | M | 75 | 10 years | |
Michael Kelly | M | 67 | 14 years | |
Kathryn Falberg | F | 63 | 6 years | |
Jay Birnbaum | M | 79 | - | |
Craig M. Audet | M | 59 | 5 years | |
Dominic P. Behan | M | 59 | 19 years | |
J. Buchi | M | 69 |
EPIRUS Biopharmaceuticals, Inc. /Old/
EPIRUS Biopharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology EPIRUS Biopharmaceuticals, Inc. develops monoclonal antibodies. It offers pharmaceutical products. The company is headquartered in Boston, MA. | 3 years |
Susan Lundeen Smuck | F | 57 | 22 years | |
Vasant Prakash Gandhi | M | - | 5 years | |
Craig Shepherd | M | - | 7 years | |
James Daly | M | 63 | 9 years | |
Cynthia Patton | F | 62 | 15 years | |
Thomas Zindrick | M | 65 | 8 years | |
Katharine Knobil | M | 60 | 2 years | |
Vincent Aurentz | M | 56 | 7 years | |
Cynthia Flowers | F | 64 | 5 years | |
Erin Lavelle | F | 46 | 15 years | |
Michael Severino | M | 58 | 10 years | |
Leonard Schaeffer | M | 78 | 9 years | |
Christine Anna White | M | 72 | 12 years | |
Martin Simonetti | M | 66 | 7 years | |
George Morrow | M | 72 | 10 years | |
Oliver Fetzer | M | 60 | 5 years | |
Phillip Schneider | M | 68 | 11 years | |
Scott H. Bice | M | 81 | 15 years | |
Kieran Gallahue | M | 60 | 4 years | |
Randall E. Woods | M | 72 | 13 years | |
Frederick Gluck | M | 88 | 13 years | |
Frank Herringer | M | 81 | 15 years | |
Donald D. Belcher | M | 84 | 14 years | |
Dominique Monnet | M | 65 | 11 years | |
Manmeet Singh Soni | M | 46 | 3 years | |
Timothy Martin | M | 55 | 3 years | |
Steven W. Spector | M | 59 | 19 years | |
Joan Schmidt | F | 60 | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 93 | 93.00% |
United Kingdom | 7 | 7.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Amit Munshi
- Personal Network